Molnupiravir for treating COVID‐19

Eleanor A. Ochodo; Eddy Owino; Bruce Nyagol; Tilly Fox; Michael McCaul; Tamara Kredo; Karen Cohen; Priscilla Rupali

doi:10.1002/14651858.cd015381

Molnupiravir for treating COVID‐19

Eleanor A. Ochodo
, Eddy Owino
, Bruce Nyagol
, Tilly Fox
, Michael McCaul
, Tamara Kredo
, Karen Cohen
, Priscilla Rupali

Clinical Sciences

Kenya Medical Research Institute
Stellenbosch University
South African Medical Research Council
University of Cape Town
Christian Medical College

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Objectives

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.

Original language	English
Article number	CD015381
Pages (from-to)	CD015381
Journal	Cochrane Database of Systematic Reviews
Volume	2022
Issue number	8
DOIs	https://doi.org/10.1002/14651858.cd015381
Publication status	Published - 8 Aug 2022

Access to Document

10.1002/14651858.cd015381

Ochodo et al-2022-Cochrane Database of Systematic ReviewsFinal published version, 225 KB

Molnupiravir for treating COVID-19
Tatz, G. S., Ochodo, E. A., Fox, T., Owino, E. J., Nyagol, B., Rupali, P., McCaul, M., Kredo, T. & Cohen, K., 28 Oct 2025, In: Cochrane Database of Systematic Reviews. 10, CD015381.
Research output: Contribution to journal › Article › peer-review

Cite this

@article{0d829bffe88444cc910a89616a8734bb,

title = "Molnupiravir for treating COVID‐19",

abstract = "ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.",

author = "Ochodo, \{Eleanor A.\} and Eddy Owino and Bruce Nyagol and Tilly Fox and Michael McCaul and Tamara Kredo and Karen Cohen and Priscilla Rupali",

year = "2022",

month = aug,

day = "8",

doi = "10.1002/14651858.cd015381",

language = "English",

volume = "2022",

pages = "CD015381",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "8",

}

TY - JOUR

T1 - Molnupiravir for treating COVID‐19

AU - Ochodo, Eleanor A.

AU - Owino, Eddy

AU - Nyagol, Bruce

AU - Fox, Tilly

AU - McCaul, Michael

AU - Kredo, Tamara

AU - Cohen, Karen

AU - Rupali, Priscilla

PY - 2022/8/8

Y1 - 2022/8/8

N2 - ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.

AB - ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:To assess the effects of molnupiravir in people with confirmed SARS‐CoV‐2 infection and mild‐to‐moderate symptoms, with or without risk factors for severe disease.

U2 - 10.1002/14651858.cd015381

DO - 10.1002/14651858.cd015381

M3 - Article

SN - 1465-1858

VL - 2022

SP - CD015381

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 8

M1 - CD015381

ER -

Molnupiravir for treating COVID‐19

Abstract

Access to Document

Fingerprint

Research output

Molnupiravir for treating COVID-19

Cite this